Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Welcome to Pump.fun!
Pump lets anyone create coins, giving everyone equal access to buy and sell from the start. Prices can move quickly, so trade carefully.
By clicking this button, you agree to the Terms and Conditions, Privacy Policy, and certify that you are over 18 years old.
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Intismeran (full name: intismeran autogene, also known as V940 or mRNA-4157) is a personalized mRNA cancer vaccine from Moderna and Merck. It is an individualized neoantigen therapy. Doctors sequence a patient’s tumor and normal DNA to identify mutations unique to that person’s cancer. An algorithm then selects up to 34 of those neoantigens and encodes them into a single synthetic mRNA molecule. Once injected, the mRNA instructs the patient’s cells to produce those cancer-specific proteins, training the immune system to recognize and attack the tumor cells. It is given together with Merck’s Keytruda (pembrolizumab), a PD-1 checkpoint inhibitor that helps keep the immune response active. The combination is currently being studied mainly in the adjuvant setting (after surgery) for high-risk melanoma, with additional trials in lung, bladder, and kidney cancers. In the Phase 3 INTerpath-001 trial in completely resected stage IIB–IV melanoma, intismeran + Keytruda reduced the risk of recurrence or death by 42% versus Keytruda alone.